Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Breast 4Thoracic 3Sarcoma 2Genitourinary 2Dermatologic 2Gynecologic 1

Conditions

Uveal Melanoma 1Neoplasm Metastasis 1Melanoma 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × STA 9090 × Dermatologic × Clear all
NCT01200238 2018-10-18

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Dana-Farber Cancer Institute

Phase 2 Completed
17 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT01551693 2017-04-12

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 7 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡